WARF: P09050US02

Novel Subtype of Botulinum Toxin for Prolonged Effectiveness


Eric Johnson, Mark Jacobson, Guangyun Lin, William Tepp, Raymond Stevens, Jerome Dupuy, Paul Stenmark

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing botulinum neurotoxin subtype A5, which may be useful for patients who have become resistant to treatment.
OVERVIEWClostridium botulinum produces botulinum neurotoxin (BoNT), which can cause debilitating disease but also is used to treat disorders like chronic headache, spastic muscles and strabismus.

Several different types of the toxin exist. Commercially available pharmaceuticals and the cosmetic agent BOTOX are derived from the A1 subtype. One problem is that patients develop resistance after repeated use. For these patients, it would be highly advantageous to find other subtypes not neutralized by their immune systems.
THE INVENTIONUW–Madison researchers have discovered and purified a novel subtype of botulinum neurotoxin, BoNT/A5. The new subtype was found in a strain of the bacteria (A661222) maintained in the researchers’ lab collection. The A5 sequence is very similar to A1; most of the differences are in areas known to interact with neutralizing antibodies. This means it may be effective even when patients have developed resistance to BOTOX and other treatments.
  • Purified botulinum neurotoxin for research, therapy and cosmetics
  • Likely used as a substitute for BoNT/A1
  • Altered immune response
  • Relatively easy to purify
STAGE OF DEVELOPMENTThe researchers have purified formulations.
Contact Information
For current licensing status, please contact Andy DeTienne at or 608-960-9857.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.